Dimitris Repantis
Dr. med.; Lead Psychedelic Substances Research Group
Data updated
Research Footprint
Dimitris Repantis appears in 7 tracked papers (2021–2026), most studied alongside Psilocybin, Placebo and 5-MeO-DMT, across Depressive Disorders, Treatment-Resistant Depression (TRD) and PTSD.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Scott Tyler Aaronson and Robin Carhart-Harris.
Background & Research
Dimitris Repantis is a physician and psychiatrist at Charité – Universitätsmedizin Berlin. He leads the Psychedelic Substances Research Group and is involved in research on psychedelic-assisted treatments, including clinical, ethical, and safety-related questions. His recent work spans psilocybin studies in depression and broader psychedelic policy and ethics discussions.
Key Impact
A psychiatrist and researcher leading psychedelic-substances work at Charité, contributing to multiple prominent psilocybin and psychedelic safety/ethics studies.
Collaboration Network
32 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Dimitris Repantis is associated with.